The breast cancer is the worldwide most commom neoplasia in women, and its malignancy centered on its highly invasive and metastatic actions. The expression of ROCK-1 is associated with malignant, whereas inhibition of this signaling molecule results in a significant suppression of tumor metastasis. Likewise, the transforming growth factor beta (TGF-²) has been linked to its power to induce epithelial-mesenchymal transition (EMT), which provides greater mobility and an invasive phenotype of these tumor cells. However, new therapeutic options have been used to inhibit these processes, in which metformin, a drug used to treat type 2 diabetes, has shown good results in research on breast cancer, reducing its incidence and prognosis favoring, through mechanisms not completely understood, but involving, among many other markers, TGF-². From the effect of TGF-² and protein expression of ROCK-1 in promoting cancer malignancy, we intend to evaluate the effects of metformin with or without the ROCK inhibitor-1, Y27632, and alternative therapies for inhibition of metastasis breast cancer in vitro.
News published in Agência FAPESP Newsletter about the scholarship: